Supramolecular hydrogels as local controlled drug delivery carriers
In recent years, macroscale drug delivery systems have been designed and investigated to spatiotemporally control the release of various bioactive agents and drugs at specific locations in the body. Many of these macroscale drug...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Net2Gel
Double network hydrogels for topical drug delivery applicati...
185K€
Cerrado
PID2019-110892RB-I00
GELES SUPRAMOLECULARES PEPTIDICOS EN LA INTERFASE CON LA PIE...
61K€
Cerrado
PROTDEL
Microfluidics Generated Hydrogel Particles for Protein Deliv...
283K€
Cerrado
D-PhosMate
Dynamic Peptide-Phosphate-based Hydrogels for Modelling Dise...
157K€
Cerrado
CTQ2016-76287-R
MATERIALES PEPTIDICOS FUNCIONALES: UNA APROXIMACION SUPRAMOL...
98K€
Cerrado
N2B-patch
Nose to Brain Delivery of Antibodies via the Olfactory Regio...
6M€
Cerrado
Información proyecto SupraCarrier
Duración del proyecto: 21 meses
Fecha Inicio: 2016-10-28
Fecha Fin: 2018-07-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
In recent years, macroscale drug delivery systems have been designed and investigated to spatiotemporally control the release of various bioactive agents and drugs at specific locations in the body. Many of these macroscale drug delivery vehicles are based on hydrogels. Depending on the location of application, and the temporal release kinetics, these hydrogel drug carriers need to be adjusted to the need of the application. Many of the currently available hydrogel systems do not have the capacity to be totally tuned. These systems: a) display a substantial initial burst release of the drug resulting in high drug doses at the initial phase; b) are difficult to apply (surgical implantation is necessary for various systems, thereby limiting their potential of easy/convenient application); c) provide only limited opportunities for chemical adjustment of their composition to improve key material properties such as their release kinetics and/or degradation rate. SupraCarrier aims to address these unmet needs by developing an injectable, supramolecular ureido-pyrimidinone (UPy) based hydrogel (UPy-hydrogel) drug delivery system that allows for local and sustained drug release. The unique selling points of this UPy-hydrogel system are: a) its demonstrated sustained drug release profile in vitro (with no initial burst release); b) its injectability due to its unique physicochemical properties (that allow for the development of clinical strategies using minimally invasive procedures); and c) its chemical structure and supramolecular assembly behaviour which allows for easy modification of either the UPy-hydrogel carrier or the drug (resulting in a versatile drug delivery platform). With SupraCarrier we aim to a) validate the commercial feasibility of a UPy-hydrogel as a novel local drug delivery system for controlled (and sustained) drug release; b) prioritise the medical applications where this system can be used; and c) provide a proof of concept for using a UPy-hydrogel